Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine.
Pantelis
C
C
Adesanya
A
A
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced*; D000927:Anticonvulsants / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003024:Clozapine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced*; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy*; D014635:Valproic Acid / Q000009:adverse effects*
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D014635:Valproic Acid; D003024:Clozapine